Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: A randomised trial

Drug Safety

Volumn 29, Issue 8, 2006, Pages 703-712

  Berthold, Heiner K ^a   Naini, Ali ^b   Di Mauro, Salvatore ^b   Hallikainen, Maarit ^c   Gylling, Helena ^c   Krone, Wilhelm ^d   Gouni Berthold, Ioanna ^d  

^a Drug Commission of the German Medical Association   (Germany)

^b NewYork Presbyterian Hospital   (United States)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; STEROL; UBIDECARENONE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; ENZYME BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LIPID ABSORPTION; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MALE; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTANOL; CHOLESTEROL; CHOLESTEROL, LDL; COENZYMES; DRUG COMBINATIONS; HUMANS; LIPID METABOLISM; LOGISTIC MODELS; MALE; MIDDLE AGED; REFERENCE VALUES; SIMVASTATIN; UBIQUINONE;

EID: 33746848052     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629080-00007     Document Type: Article

References (31)

1. Nohl H, Staniek K, Kozlov AV, et al. The biomolecule ubiquinone exerts a variety of biological functions. Biofactors 2003; 18 (1-4): 23-31
2. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990; 87 (22): 8931-4
3. Laaksonen R, Ojala JP, Tikkanen MJ, et al. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46 (4): 313-7
4. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995; 57 (1): 62-6
5. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997; 18 Suppl.: S137-44
6. Hargreaves IP, Duncan AJ, Heales SJ, et al. The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Saf 2005; 28 (8): 659-76
7. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002; 62 (16): 2333-47
8. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106 (15): 1943-8
9. Havranek JM, Wolfsen AR, Warnke GA, et al. Monotherapy with ezetimibe causing myopathy. Am J Med 2006; 119 (3): 285-6
10. Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol 2006; 22 (2): 141-4
11. Fux R, Morike K, Gundel UF, et al. Ezetimibe and statin-associated myopathy. Ann Intern Med 2004; 140 (8): 671-2
12. Miettinen TA, Tilvis RS, Kesaniemi Y. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131 (1): 20-31
13. Gylling H, Miettinen TA. Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 2002; 43 (9): 1472-6
14. Naini A, Lewis VJ, Hirano M, et al. Primary coenzyme Q10 deficiency and the brain. Biofactors 2003; 18 (1-4): 145-52
15. Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004; 61 (6): 889-92
16. Koumis T, Nathan JP, Rosenberg JM, et al. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation? Am J Health Syst Pharm 2004; 61 (5): 515-9
17. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90
18. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40 (12): 2125-34
19. Human JA, Ubbink JB, Jerling JJ, et al. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta 1997; 263 (1): 67-77
20. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46 (11): 1055-7
21. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57 (3): 515-8
22. DePinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42 (3): 333-7
23. Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med 1981; 305 (9): 478-82
24. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2005; 94: 1306-10
25. Kalen A, Appelkvist EL, Dallner G. The effects of inducers of the endoplasmic reticulum peroxisomes and mitochondria on the amounts and synthesis of ubiquinone in rat liver subcellular membranes. Chem Biol Interact 1990; 73: 221-34
26. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG-CoA reductase: a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 1980; 21: 505-17
27. Elmberger PG, Kalen A, Lund E, et al. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991; 32 (6): 935-40
28. Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gammatocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998; 28 (3): 235-42
29. De Lorgeril M, Salen P, Bontemps L, et al. Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999; 33: 473-8
30. Aberg F, Zhang Y, Appelkvist EL, et al. Effects of clofibrate, phthalates and probucol on ubiquinone levels. Chem Biol Interact 1994; 91: 1-14
31. Laaksonen R, Riihimaki A, Laitila J, et al. Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med 1995; 125: 517-21